Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence-Reference-Cited by-同舟云学术

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

Published:2011-02-01 Issue:3 Volume:11 Page:305-312
ISSN:1528-4042
Container-title:Current Neurology and Neuroscience Reports
language:en
Short-container-title:Curr Neurol Neurosci Rep

Author:

Wick Wolfgang,Wick Antje,Weiler Markus,Weller Michael

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),General Neuroscience

Link

http://link.springer.com/content/pdf/10.1007/s11910-011-0184-0.pdf

Reference45 articles.

1. •• Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733–40. This is the final report of the BRAIN trial, which represents the major clinical data leading to approval of BEV for recurrent glioblastoma in several countries outside the European Union.

2. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.

3. • Wick W, Weller M, van den Bent M, Stupp R: Avastin and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010, 28:188–90. This is a critical letter summarizing the European perspective on the approval of BEV.

4. Summary Minutes of the Oncologic Drugs Advisory Committee March 31, 2009. In: Center for Drug Evaluation and Research ed. Washington: Food and Drug Administration 2009

5. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local and global sensitivity analysis of spheroid and xenograft models of the acid-mediated development of tumor malignancy;Applied Mathematical Modelling;2022-09

2. A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles;Proceedings of the National Academy of Sciences;2022-06

3. Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review;International Journal of Nanomedicine;2021-07

4. Lysophospholipid Signalling and the Tumour Microenvironment;Advances in Experimental Medicine and Biology;2020-10-30

5. Vessel co-option and resistance to anti-angiogenic therapy;Angiogenesis;2019-12-21